Immuron Limited (IMC) Reports Unaudited Double-Digit Q1 Sales Growth

Immuron (IMRN) published Phase 2 Travelan trial results in Scientific Reports. The study showed a 50% reduction in ETEC-related adverse events but missed its primary endpoint. Despite this, several clinical outcomes favored Travelan. The stock is down 5.69% in pre-market trading.

Immuron (IMC) released Phase 2 data for Travelan, showing safety and a 50% reduction in adverse events, but missed primary endpoints due to a low placebo attack rate. The company may need a larger study to create a significant catalyst.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) published Phase 2 trial results for Travelan® in the Nature Journal, showing a 50% reduction in severe diarrhea but missing primary goals. The study, partially funded by the U.S. Department of Defense, found Travelan® safe and well-tolerated, with significant reductions in diarrhea severity and antibiotic use. Immuron is developing a next-generation formulation and advancing Travelan® as a non-antibiotic treatment for bacterial diarrheal diseases.

Immuron (IMRN) shares rose 56% to $1.7350 after announcing a U.S. distribution deal for PROIBS with Calmino. PROIBS, a digestive health product, had a 94% helpfulness rate in a Calmino study. Immuron's stock volume reached 95.65 million shares, far above its average.

Immuron Ltd (IMRN) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 Immuron FY26 Preliminary Results Melbourne, Australia, August 28, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed expectations In February 2026 at the time the Company

Boeing reported a narrower Q3 net loss of $116M ($0.26/ share) vs. a $5.34B loss last year, with operating profit and revenue up 4% to $24.19B. Commercial Airplanes revenue fell 3% to $10.72B, while defense and services revenues grew. Shares dropped 3.64% to $181.45.